NCT02259946View on ClinicalTrials.gov

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

July 31, 2006

Conditions
Healthy
Interventions
DRUG

BI 1744 CL

DRUG

Placebo

DRUG

Tiotropium bromide

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY